Kura Oncology (KURA) FCF Margin (2025 - 2026)
Kura Oncology's (KURA) quarterly FCF Margin came in at 470.75% in Q1 2026, up 4115.0% year-on-year from 11.17% in Q1 2025, and down 170.99% on a QoQ basis from 663.08% in Q4 2025.
Kura Oncology (KURA) FCF Margin (2025 - 2026) Analysis & Trends
Kura Oncology (KURA) has 2 years of FCF Margin data on file, last reported at 470.75% in Q1 2026.
- On a quarterly basis, FCF Margin rose 4115.0% year-over-year to 470.75% in Q1 2026; TTM through Mar 2026 was 117.9%, a N/A change from a year earlier, with the FY2025 full-year figure at 104.76%, down 35316.0% from the prior year.
- FCF Margin for Q1 2026 stood at 470.75%, down from 663.08% in the prior quarter.
- Over the last five years, FCF Margin for KURA reached as high as 663.08% in Q4 2025 and fell as low as 511.9% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Kura Oncology | 925.97 Mn | 925.97 Mn | 18.00 Mn | -470.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -470.75% |
| Dec 31, 2025 | 663.08% |
| Sep 30, 2025 | -400.93% |
| Jun 30, 2025 | -197.77% |
| Mar 31, 2025 | -511.90% |